Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flavored vapes tested as smoking cessation aid – but study ends early

NCT ID NCT07172438

Disease control Sponsor: RAI Services Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if giving smokers access to different e-cigarette flavors (menthol, non-tobacco, or tobacco) helps them stop smoking regular cigarettes. Over 600 adult smokers were assigned to different flavor groups and tracked for 13 weeks. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
electronic nicotine delivery system (ENDS) with various e-liquid flavors
What this could lead to
If successful, this could show that offering a choice of flavors in e-cigarettes helps more smokers switch away from combustible cigarettes.
What could go wrong
The study was terminated early, so we may not get clear answers. Also, e-cigarettes carry their own health risks and may not help everyone quit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

668 people

The number who actually took part.

Started

Sep 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to read, understand, and are willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English 2. Generally healthy male or female, between 21 and 65 years of age, inclusive, at the time of consent 3. All female (assigned at birth) candidate participants who agree during the pre-screener to receive and take a home pregnancy test prior to the SEV, and who affirm at the SEV that they are not pregnant or intending to become pregnant. NOTE: Participants who identify as "intersex" or "unknown" during screening, will be offered the opportunity to receive a pregnancy test if they wish to take one. 4. Currently smoke at least 10 cigarettes on smoking days in the past 30 days 5. Smoke cigarettes regularly for at least 12 months 6. Smoke cigarettes on 15 or more of the past 30 days 7. Smoked at least 100 cigarettes in their lifetime prior to the screening and enrollment visit. 8. Must indicate smoking factory-made filtered menthol and/or non-menthol cigarettes as their primary nicotine product (Occasional use of other tobacco- or nicotine-containing products is acceptable) 9. Indicate a willingness to use ENDS 10. Agree to participate in the study and to abide by the study restrictions and requirements, as described in the informed concent form (ICF) Exclusion Criteria: 1. Female participants who are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report. 2. Female participants who self-report not using adequate methods to prevent pregnancy 3. Persons with pacemakers or other embedded electronic medical devices fitted 4. Persons who self-report heart disease, high blood pressure, diabetes, cancer, Chronic Obstructive Pulmonary Disease, emphysema, asthma or other lung/breathing conditions, a previous history of heart attack or stroke, or are taking medication for depression. 5. Persons who self-report they are allergic/sensitive to cosmetics or fragrances or to any ingredient listed in Vuse commercial products or similar products, including those listed below: 1. Carvone (L-) 2. Benzyl alcohol 6. Participants who have used ENDS, nicotine pouch or smokeless tobacco (i.e., chewing tobacco, snus, or snuff) products on 5 or more days in the past 30 days 7. Participants who have used ENDS, nicotine pouch or smokeless tobacco products more than 100 times in their lifetime 8. Participants who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days. 9. Employee of a company that manufactures tobacco or ENDS products 10. Persons who are personally, have household members, or have close family or friends in litigation with a company that manufactures tobacco or ENDS products 11. Have taken part in a tobacco/nicotine research study in the past 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Smoking are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nicotine dependence Smoking Tobacco Smoking Tobacco Use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Smoking Tobacco

Contacts and locations

Locations

  • C&C-Arlington

    Arlington, Texas, 76015, United States

  • C&C-Fort Smith

    Fort Smith, Arkansas, 72908, United States

  • C&C-Humble

    Humble, Texas, 77338, United States

  • C&C-Lombard

    Lombard, Illinois, 60148, United States

  • C&C-Mesquite

    Mesquite, Texas, 75150, United States

  • C&C-Philadelphia

    Philadelphia, Pennsylvania, 19154, United States

  • C&C-Plantation

    Plantation, Florida, 33388, United States

  • C&C-Richmond Heights

    St Louis, Missouri, 63117, United States

  • C&C-San Antonio

    San Antonio, Texas, 78216, United States

  • C&C-San Antonio

    San Antonio, Texas, 78224, United States

  • C&C-Sebring

    Sebring, Florida, 33870, United States

  • C&C-Tallahassee

    Tallahassee, Florida, 32301, United States

  • C&C-Tampa

    Clearwater, Florida, 33761, United States

  • C&C-Troy

    Troy, Michigan, 48083, United States

  • CRG Test America-Grapevine

    Grapevine, Texas, 76051, United States

  • CRG Test America-Ormond Beach

    Ormond Beach, Florida, 32174, United States

  • CRG Test America-Pembroke Pines

    Miami, Florida, 33026, United States

  • CRG Test America-Phoenix

    Chandler, Arizona, 85226, United States

  • CRG Test America-St. Peters

    City of Saint Peters, Missouri, 63376, United States

  • CRG Test America-Tampa

    Tampa, Florida, 33609, United States

  • Research America Orlando

    Altamonte Springs, Florida, 32701, United States

  • Sago Dallas

    Dallas, Texas, 75254, United States

  • Sago Houston

    Houston, Texas, 77027, United States

  • Sago Orlando

    Maitland, Florida, 32751, United States

  • Sago Philadelphia

    Philadelphia, Pennsylvania, 19103, United States

  • Sago St. Louis

    St Louis, Missouri, 63131, United States

  • Southern Solutions Knoxville

    Knoxville, Tennessee, 37922, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.